AR067770A1 - Derivados de tiazol y ditiazol para el tratamiento de diabetes - Google Patents

Derivados de tiazol y ditiazol para el tratamiento de diabetes

Info

Publication number
AR067770A1
AR067770A1 ARP080103342A ARP080103342A AR067770A1 AR 067770 A1 AR067770 A1 AR 067770A1 AR P080103342 A ARP080103342 A AR P080103342A AR P080103342 A ARP080103342 A AR P080103342A AR 067770 A1 AR067770 A1 AR 067770A1
Authority
AR
Argentina
Prior art keywords
diabetes
treatment
ditiazol
tiazol
derivatives
Prior art date
Application number
ARP080103342A
Other languages
English (en)
Inventor
Anders Eriksson
Jacob Westman
Original Assignee
Betagenon Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon Ab filed Critical Betagenon Ab
Publication of AR067770A1 publication Critical patent/AR067770A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dichos compuestos son potencialmente de utilidad en el tratamiento de trastornos o condiciones causadas por, ligadas a o en los que contribuye una adiposidad excesiva, tal como hiperinsulinemia y diabetes tipo 2. Reivindicacion 1: Un compuesto, caracterizado porque es de la formula 1, en donde: Y representa -C(O)- o -S(O)2-, o una sal o solvato aceptable para uso farmacéutico o un derivado farmacéuticamente funcional de los mismos.
ARP080103342A 2007-08-03 2008-07-31 Derivados de tiazol y ditiazol para el tratamiento de diabetes AR067770A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93527007P 2007-08-03 2007-08-03

Publications (1)

Publication Number Publication Date
AR067770A1 true AR067770A1 (es) 2009-10-21

Family

ID=38646552

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080103341A AR067769A1 (es) 2007-08-03 2008-07-31 Derivado de ditiazol para el tratamiento del cancer
ARP080103342A AR067770A1 (es) 2007-08-03 2008-07-31 Derivados de tiazol y ditiazol para el tratamiento de diabetes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP080103341A AR067769A1 (es) 2007-08-03 2008-07-31 Derivado de ditiazol para el tratamiento del cancer

Country Status (5)

Country Link
US (1) US20110177046A1 (es)
EP (1) EP2183233A1 (es)
AR (2) AR067769A1 (es)
TW (2) TW200918049A (es)
WO (2) WO2009019445A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US8871699B2 (en) 2012-09-13 2014-10-28 Ecolab Usa Inc. Detergent composition comprising phosphinosuccinic acid adducts and methods of use
US9994799B2 (en) 2012-09-13 2018-06-12 Ecolab Usa Inc. Hard surface cleaning compositions comprising phosphinosuccinic acid adducts and methods of use
US9752105B2 (en) 2012-09-13 2017-09-05 Ecolab Usa Inc. Two step method of cleaning, sanitizing, and rinsing a surface
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
CN110250110A (zh) * 2019-07-11 2019-09-20 南京医科大学附属逸夫医院 一种顺铂所致急性肾损伤的小鼠模型的构建方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200800302A1 (ru) * 2005-07-21 2008-08-29 Бетагенон Аб Применение производных и аналогов тиазола при лечении рака

Also Published As

Publication number Publication date
EP2183233A1 (en) 2010-05-12
WO2009019446A1 (en) 2009-02-12
TW200920361A (en) 2009-05-16
US20110177046A1 (en) 2011-07-21
WO2009019445A1 (en) 2009-02-12
AR067769A1 (es) 2009-10-21
TW200918049A (en) 2009-05-01

Similar Documents

Publication Publication Date Title
AR067770A1 (es) Derivados de tiazol y ditiazol para el tratamiento de diabetes
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
ECSP066653A (es) Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad
ECSP088871A (es) Derivados de triazolopirazina
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
EA200701745A1 (ru) Циклопропанкарбоксамидные производные
ECSP12011582A (es) Terapia de combinación para el tratamiento de la diabetes
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
ECSP11011398A (es) Inhibidores de beta-secretasa
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
CU23850B1 (es) Composiciones farmacéuticas estabilizadas que comprenden fesoterodina
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR110128A2 (es) Compuesto del grupo de las 3-(imidazoil)-pirazolo[3,4-b]piridinas, composición farmacéutica que lo comprende y método para preparar el mismo
AR061134A1 (es) Derivados de tioxantina
SV2010003464A (es) Derivados de pirimida utiles para el tratamiento de condiciones inflamatorias o alergicas
ECSP088457A (es) Compuestos de benzamida útiles como inhibidores de la histona deacetilasa
ECSP067044A (es) Compuestos para el tratamiento de trastornos inflamatorios
CO6140054A2 (es) Compuestos de dialquilfenilo con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico
CL2007003042A1 (es) Compuestos derivados del acido tetrahidro-naftalen-1-carboxilico sustituidos con piperidina o piperazina; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica; procedimiento de preparacion; y uso para el tratamiento de arte
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
BRPI0811204A8 (pt) Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib

Legal Events

Date Code Title Description
FB Suspension of granting procedure